NCT06190301

RCT on Intralesional Rituximab Injection Versus ISRT in Ocular Adnexal MALT Lymphoma

Safety and Efficacy of Intralesional Rituximab Injection Versus Involved Site Radiation Therapy in Primary Ocular Adnexal MALT Lymphoma: a Multicenter Randomized Controlled Trial

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 108 (estimated)
• Sponsor: Zhongshan Ophthalmic Center, Sun Yat-sen University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This project proposes to establish a prospective, multicenter, randomized, controlled clinical study to compare the safety and efficacy of Intralesional Rituximab Injection versus Involved Site Radiation Therapy for the treatment of primary ocular adnexal MALT lymphoma. The aim is to provide high-level clinical evidence for the treatment of ocular adnexal MALT lymphoma and to offer patients treatment options that have fewer complications and comparable therapeutic effects.

Conditions

• Primary Ocular Adnexal MALT Lymphoma

Interventions

Type	Name	Description
DRUG	Rituximab	Intralesional Rituximab Injection
RADIATION	Involved Site Radiation Therapy	Involved Site Radiation Therapy

Timeline

• Start date: 2023-12-20
• Primary completion: 2029-12-31
• Completion: 2029-12-31
• First posted: 2024-01-05
• Last updated: 2026-04-20

Locations

1 site across 1 country: China